Programmed cell death ligand 1 (PD-L1) expression on tumor cells is often observed in human cancers, and its binding to the programmed cell death-1 (PD-1) on activated T cells inhibits T cell proliferation, survival, cytokine production, and other effector functions, and ultimately inhibits anti-tumor immune responses1,2. The gene discussed is PDCD1; the disease is cancer.